Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.

ABSTRACT: It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment. Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks. Consequently, additional novel therapeutic targets are increasingly sought. A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation. Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings. Accordingly, it has been s

SUBMITTER: MacNabb C 

PROVIDER: S-EPMC4899597 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature